Total value of the contracts for Galapagos is $1 million over 1.5 years. Galapagos’s service division, BioFocus DPI, will develop a high throughput screening assay in mouse neurons that will enable the identification of compounds that prevent neuronal dysfunction associated with Huntington’s disease (HD).
BioFocus DPI will also make use of its expertise in profiling and assay development to evaluate known compounds inhibiting certain enzymes playing key roles in HD. These new programs continue the collaboration started in August 2005.
Onno Stolpe, CEO of Galapagos, said: “The new programs initiated with CHDI demonstrate how innovative BioFocus DPI is in its drug discovery expertise. With its growing list of patient organizations in the client base, our service division continues to build on its reputation for high quality drug discovery.”